Stockscreener 앱 받기
0.4502
2.70%
-0.0125
전일 마감가:
$0.4627
열려 있는:
$0.47
하루 거래량:
176.10K
Relative Volume:
0.51
시가총액:
$18.80M
수익:
$20.27M
순이익/손실:
$-63.80M
주가수익비율:
-0.2962
EPS:
-1.52
순현금흐름:
$-68.35M
1주 성능:
-8.50%
1개월 성능:
-2.13%
6개월 성능:
-63.98%
1년 성능:
-81.62%
1일 변동 폭
$0.4401
$0.48
1주일 범위
$0.4401
$0.4998
52주 변동 폭
$0.38
$2.77
Carisma Therapeutics Inc Stock (CARM) Company Profile
명칭
Carisma Therapeutics Inc
전화
(267) 491-6422
주소
3675 MARKET STREET, PHILADELPHIA
CARM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CARM
Carisma Therapeutics Inc
|
0.4502 | 18.80M | 20.27M | -63.80M | -68.35M | -1.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Carisma Therapeutics Inc Stock (CARM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-12 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-12-10 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-04-11 | 개시 | BTIG Research | Buy |
| 2023-10-03 | 개시 | CapitalOne | Overweight |
| 2023-07-06 | 개시 | Evercore ISI | Outperform |
| 2023-05-31 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-05-24 | 개시 | H.C. Wainwright | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
모두보기
Carisma Therapeutics Inc 주식(CARM)의 최신 뉴스
Michael Klichinsky to Speak at H.C. Wainwright Cell Therapy Virtual Conference - MSN
Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 - Quantisnow
Carisma Therapeutics to Participate in H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference - Quantisnow
Carisma Therapeutics to Present at Oppenheimer’s 35th Annual Healthcare Conference - MSN
Carisma Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference - Quantisnow
Carisma Therapeutics, Inc. (NASDAQ:CARM) Short Interest Update - Defense World
Carisma Therapeutics, Inc. (NASDAQ:CARM) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Layoff Tracker: Biogen to Cut Undisclosed Number of Research Employees - BioSpace
BTIG Downgrades Carisma Therapeutics (CARM) - MSN
Evercore ISI Group Downgrades Carisma Therapeutics (CARM) - MSN
Barclays PLC Has $539,000 Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics (NASDAQ:CARM) Given “Buy” Rating at D. Boral Capital - Defense World
Geode Capital Management LLC Lowers Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics faces Nasdaq delisting over share price - Investing.com India
Carisma Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Canada
Carisma Therapeutics, Inc. (NASDAQ:CARM) Receives Average Rating of “Hold” from Analysts - Defense World
Barclays PLC Grows Holdings in Carisma Therapeutics, Inc. (NASDAQ:CARM) - Defense World
Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 - GuruFocus.com
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology - Quantisnow
Carisma Therapeutics Appoints Interim VP of Finance - TipRanks
Carisma Therapeutics Refocuses Strategy, Reduces Workforce Amid Pipeline Reprioritization - MSN
Carisma downgraded by H.C. Wainwright to neutral - MSN
Carisma Therapeutics (NASDAQ:CARM) Given Neutral Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Carisma Therapeutics (CARM) - MSN
Carisma shares downgraded to neutral after program halt - Investing.com
Carisma Therapeutics (NASDAQ:CARM) Cut to Neutral at Robert W. Baird - Defense World
Carisma downgraded by Baird over lack of near-term catalysts - MSN
Carisma Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference - Kilgore News Herald
Baird Downgrades Carisma Therapeutics (CARM) - MSN
BTIG cuts Carisma Therapeutics to Neutral from Buy By Investing.com - Investing.com Nigeria
Carisma downgraded by Baird over lack of near-term catalysts (CARM:NASDAQ) - Seeking Alpha
Carisma Therapeutics downgraded to Neutral from Outperform at Baird - MSN
Baird cautious on Carisma stock after pivot away from lead CAR-M program - Investing.com
Carisma Therapeutics Announces Upcoming Presentations at SITC 2024 - The Eastern Progress Online
Carisma Therapeutics cut to In Line, stock target slashed on tempered outlook - Investing.com
Carisma Therapeutics Drops GC As Part Of Cutbacks - Law360
Carisma Therapeutics Announces Strategic Restructuring to Re-Prioritize Pipeline and A Reduction in the Workforce by 34% - Marketscreener.com
Carisma Therapeutics shifts focus, cuts workforce by 34% - Investing.com Nigeria
Carisma Therapeutics to Cut 34% of Staff, Reprioritize Pipeline - BioSpace
Carisma Therapeutics Inc (CARM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
3.05%
자본화:
|
볼륨(24시간):